By AuntMinnie.com staff writers

October 6, 2016 -- GE Healthcare has received approval from the U.S. Food and Drug Administration (FDA) for a label change for its Optison ultrasound contrast agent.

The FDA removed the contraindications for use in patients with cardiac shunts and for administration by intra-arterial injection. A cardiac shunt is a pattern of blood flow in the heart that deviates from the normal flow of the circulatory system.

With suspected cardiac shunt populations, an agitated saline procedure previously was needed to determine if a shunt existed and whether the patient was contraindicated to receive an ultrasound contrast agent.


Copyright © 2016 AuntMinnie.com
 

To read this and get access to all of the exclusive content on AuntMinnie.com create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking
account: